Loading clinical trials...
Loading clinical trials...
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Matinas BioPharma Nanotechnologies, Inc.
NCT06835361 · Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC)
NCT06978907 · Atrophic Vulvovaginitis
NCT04219605 · Bacterial Vaginosis, Candida Albicans Vulvovaginitis, and more
NCT06572488 · Candidiasis, Vulvovaginal, Candidiasis of Vagina, and more
NCT03253094 · Candida Vulvovaginitis
Tolan Park Clinic
Detroit, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions